22528-34-3

Usage

Uses

Used in Pharmaceutical Industry:
3-AMINO-4'-NITRODIPHENYL ETHER is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs. Its chemical structure allows it to be a building block in the creation of various medicinal compounds.
Used in Dye Industry:
In the dye industry, 3-AMINO-4'-NITRODIPHENYL ETHER is utilized as an intermediate, playing a crucial role in the production of different types of dyes. Its chemical composition is beneficial in the formation of colorants used in various applications.
Used in Chemical Research:
3-AMINO-4'-NITRODIPHENYL ETHER is employed as a reagent in chemical research, where it aids in the investigation of organic synthesis and the development of novel chemical reactions and processes.
Used in Organic Synthesis:
As a reagent in organic synthesis, 3-AMINO-4'-NITRODIPHENYL ETHER is used to facilitate specific chemical reactions, contributing to the formation of desired organic compounds.
Used in Antimicrobial Applications:
3-AMINO-4'-NITRODIPHENYL ETHER has been studied for its potential antimicrobial properties, suggesting its use in applications that require the inhibition of microbial growth.
Used in Antitumor Applications:
3-AMINO-4'-NITRODIPHENYL ETHER has also been researched for its possible antitumor properties, indicating a potential role in the development of treatments for cancer.

Upstream product

• 22483-34-7 acetic acid-[3-(4-nitro-phenoxy)-anilide] 
• 350-46-9 4-Fluoronitrobenzene 
• 591-27-5 m-Hydroxyaniline 
• 586-78-7 para-nitrophenyl bromide 
• 76506-19-9 Potassium; 3-acetylamino-phenolate 

Downstream Products

• 56705-88-5 N,N-dimethyl-3-(4-nitro-phenoxy)-aniline 
• 17076-74-3 3'-Cyano-4-Nitrodiphenylether 
• 2303-23-3 1-chloro-3-(4-nitrophenoxy)benzene 
• 738614-92-1 N,N'-bis-[3-(4-amino-phenoxy)-phenyl]-terephthalamide 
• 22483-31-4 3-(4-Nitrophenoxy)phenol 
• 2657-87-6 3,4'-diaminodiphenyl ether 
• 1123580-82-4 N-[3-(4-aminophenoxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide 
• 1123580-77-7 3-(1-cyano-1-methylethyl)-N-[3-({2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}oxy)phenyl]benzamide 
• 1123580-84-6 N-{3-[(2-amino-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide 
• 1123580-80-2 3-(1-cyano-1-methylethyl)-N-[3-(4-nitrophenoxy)phenyl]benzamide 

Relevant academic research and scientific papers

Exploring the anti-cancer mechanism of novel 3,4′-substituted diaryl guanidinium derivatives

We previously identified a guanidinium-based lead compound that inhibited BRAF through a hypothetic type-III allosteric mechanism. Considering the pharmacophore identified in this lead compound (i.e., “lipophilic group”, “di-substituted guanidine”, “phenylguanidine polar end”), several modifications were investigated to improve its cytotoxicity in different cancer cell lines. Thus, several lipophilic groups were explored, the di-substituted guanidine was replaced by a secondary amine and the phenyl ring in the polar end was substituted by a pyridine. In a structure-based design approach, four representative derivatives were docked into an in-house model of an active triphosphate-containing BRAF protein, and the interactions established were analysed. Based on these computational studies, a variety of derivatives was synthesized, and their predicted drug-like properties calculated. Next, the effect on cell viability of these compounds was assessed in cell line models of promyelocytic leukaemia and breast, cervical and colorectal carcinomas. The potential of a selection of these compounds as apoptotic agents was assessed by screening in the promyelocytic leukaemia cell line HL-60. The toxicity against non-tumorigenic epithelial MCF10A cells was also investigated. These studies allowed for several structure-activity relationships to be derived. Investigations on the mechanism of action of representative compounds suggest a divergent effect on inhibition of the MAPK/ERK signalling pathway.

Design and synthesis of novel DFG-Out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors. 1. Exploration of [5,6]-fused bicyclic scaffolds

To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-b]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, 1-6) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-b]pyridine derivative 6d showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of 6d (6d-SD) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (T/C = -7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that 6d is a promising RAF/VEGFR2 inhibitor showing potent anticancer activity.

HETEROCYCLIC COMPOUND AND USE THEREOF

Disclosed is a heterocyclic compound having a strong Raf inhibitory activity. Specifically disclosed is a compound represented by the formula (I), (II) or (III) below, or a salt thereof. (In the formulae, the symbols are as defined in the description.)